Synapse - Works

Results (115372)

Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119

Meeting Abstract

Bar-Natan, M.; Mascarenhas, J.; Gerds, A. T.; Mesa, R.; Gupta, V.; Kremyanskaya, M.; Dougherty, M.; Fabris, F.; Johnson, K.; Yu, A.; more...
Blood (2022)

Fulltext@MSK | Save

Impact on tumour treatment and outcome of SARS-CoV-2 infection in 91 patients with primary CNS lymphoma: A real-life study of the international PCNSL Collaborative Group

Meeting Abstract

Calimeri, T.; Steffanoni, S.; Laurenge, A.; Fox, C. P.; Soussain, C.; Grommes, C.; Tisi, M. C.; Boot, J.; Crosbie, N.; Visco, C.; more...
Blood (2022)

Fulltext@MSK | Save

Phase Ib/II trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, in combination with rituximab and lenalidomide in refractory/recurrent primary (PCNSL) and secondary central nervous system lymphoma (SCNSL)

Meeting Abstract

Grommes, C.; Piotrowski, A.; Pentsova, E.; Gavrilovic, I.; Stone, J. B.; Lin, A.; Wongchai, V.; Madzsar, J. T.; Malani, R.; Nolan, C.; more...
Blood (2022)

Fulltext@MSK | Save

Escape from type II JAK2 inhibition in MPN depends on AXL/MAPK activation and is targetable

Meeting Abstract

Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J.; Ghosh, N.; Buczak, K.; Passweg, J.; Angelillo-Scherrer, A.; Dirnhofer, S.; more...
Blood (2022)

Fulltext@MSK | Save

Subcutaneous mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs): Updated results from a phase I/II study

Meeting Abstract

Budde, E. L.; Bartlett, N. L.; Giri, P.; Schuster, S. J.; Assouline, S.; Yoon, S. S.; Fay, K.; Matasar, M. J.; Gutierrez, N. C.; Marlton, P.; more...
Blood (2022)

Fulltext@MSK | Save

Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling

Meeting Abstract

Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant

Meeting Abstract

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Long-term outcome of patients with follicular lymphoma is not fundamentally affected by KMT2D, EZH2, and CREBBP mutational status

Meeting Abstract

Bantilan, K. S.; Rutherford, K.; McCarter, J.; Farnoud, N.; Arango-Ossa, J. E.; Papaemmanuil, E.; Zelenetz, A. D.
Blood (2022)

Fulltext@MSK | Save

Population pharmacokinetics and exposure-response analyses from Phase I-III studies support copanlisib dose selection in relapsed indolent non-Hodgkin lymphoma

Meeting Abstract

Moss, J.; Garmann, D.; Austin, R.; Hiemeyer, F.; Matasar, M. J.; Zinzani, P. L.; Beckert, V.; Soler, L. M.; Childs, B. H.; Morcos, P. N.
Blood (2022)

Fulltext@MSK | Save